Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 19-Jun-2013
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 11)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
19-Jun-13 ValuEngine, Inc. N/A ValuEngine Industry Report for Medical-drugs 18 $207 View Abstract
15-Jun-13 S&P Capital IQ Quantitative Report N/A EpiCept Corp 6 $69 View Abstract
14-Jun-13 Reuters Investment Profile N/A EpiCept Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
14-Jun-13 Wright Reports N/A Wright Industry Averages: Pharmaceuticals & Biotechnology (Global) 105 $1207.50 View Abstract
14-Jun-13 Wright Reports N/A Wright Industry Averages: Pharmaceuticals & Biotechnology (North America) 78 $897 View Abstract
14-Jun-13 Wright Reports N/A Wright Industry Averages: Pharmaceuticals & Biotechnology (United States) 77 $885.50 View Abstract
13-Jun-13 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for EPCT 11 $126.50 View Abstract
5-Jun-13 Edison Investment Research Mr. Neil Shah, Stephen Rogers, Jane Anscombe, Nigel Harrison, Mr. Roger Leboff, Martin Lister, Mr. Robin Davison, Ms. Fiona Orford-Williams, Mr. Richard Finch, Mr. Anthony Wagg, Dr. John Savin, Mr. Jacob Plieth, Guy Bell, Maana Ruia, Mr. Richard Jeans, Mr. Charles Gibson, Emma Ulker, Mr. Matthew Read, Mr. Peter J Dupont, Dr. Wang Chong, Elaine Reynolds, Ms. Lala Gregorek, Ms. Katherine Thompson, Mr. Roger Johnston, Dr. Mick Cooper, Graeme Moyse, Mr. Toby Thorrington, Mr. Martyn King, Mr. Mark Thomas, Dan Ridsdale, Mr. Ian McLelland, Edwin Llyold, Mr. Tom Hayes, Mr. Derek Terrington, Research Team, Julian Emery, Ms. Krisztina Kovacs, Mr. Andrey Litvin, Rory Draper, Dr. Andrew Fellows, Mr. Peter Darling, Mr. Colin McEnery, Christian Glennie, Ms. Anne Margaret Crow, Jonathan Goslin, Sheldon Modeland, Mr. Chris Kallos, Mr. Peter Thorne, Ms. Bridie Barratt Schmidt, Imran Akram, Mr. John Buckland, Mr. Arun George, Andrew Saunders, John Kidd, Mr. Will Forbes, Alastair George, Mr. Mark Cartlich, Franc Gregori, James Carthew, Dr. Michael Aitkenhead, Mr. Gavin Wood, Dr. Jason Zhang, Zsolt Mester, Luke Poloniecki, Pooya Hemami, Mr. Peter Chilton, Dr. Philippa Gardner, Iain Daly, Amit Dayal, Mark Hodges, Bruce McKay, Teea Reijonen, Rob Kirtley, Graeme Kyle, Victoria Buxton, Ian Kellett, Andrew Mitchell, Mr. Michael Stoner, Ian Berry, Ian Mitchell, Jonathan Helliwell, Toby Gordon, Wayne Atwell, William Atcheson, Xavier Grunauer MAY 2013 EDITION OF EDISON INSIGHT 152 $10 View Abstract
30-May-13 S&P Capital IQ Factual Report N/A EpiCept Corp 11 $126.50 View Abstract
30-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Epicept Corporation 40 $460 View Abstract
Next 1

Independent Reports (Showing 1 to 10 of 11)

Release
Date Contributor Author Title Pages Price More Info
19-Jun-13 ValuEngine, Inc. N/A ValuEngine Industry Report for Medical-drugs 18 $207 View Abstract
15-Jun-13 S&P Capital IQ Quantitative Report N/A EpiCept Corp 6 $69 View Abstract
14-Jun-13 Reuters Investment Profile N/A EpiCept Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $138 View Abstract
14-Jun-13 Wright Reports N/A Wright Industry Averages: Pharmaceuticals & Biotechnology (Global) 105 $1207.50 View Abstract
14-Jun-13 Wright Reports N/A Wright Industry Averages: Pharmaceuticals & Biotechnology (North America) 78 $897 View Abstract
14-Jun-13 Wright Reports N/A Wright Industry Averages: Pharmaceuticals & Biotechnology (United States) 77 $885.50 View Abstract
13-Jun-13 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for EPCT 11 $126.50 View Abstract
5-Jun-13 Edison Investment Research Mr. Neil Shah, Stephen Rogers, Jane Anscombe, Nigel Harrison, Mr. Roger Leboff, Martin Lister, Mr. Robin Davison, Ms. Fiona Orford-Williams, Mr. Richard Finch, Mr. Anthony Wagg, Dr. John Savin, Mr. Jacob Plieth, Guy Bell, Maana Ruia, Mr. Richard Jeans, Mr. Charles Gibson, Emma Ulker, Mr. Matthew Read, Mr. Peter J Dupont, Dr. Wang Chong, Elaine Reynolds, Ms. Lala Gregorek, Ms. Katherine Thompson, Mr. Roger Johnston, Dr. Mick Cooper, Graeme Moyse, Mr. Toby Thorrington, Mr. Martyn King, Mr. Mark Thomas, Dan Ridsdale, Mr. Ian McLelland, Edwin Llyold, Mr. Tom Hayes, Mr. Derek Terrington, Research Team, Julian Emery, Ms. Krisztina Kovacs, Mr. Andrey Litvin, Rory Draper, Dr. Andrew Fellows, Mr. Peter Darling, Mr. Colin McEnery, Christian Glennie, Ms. Anne Margaret Crow, Jonathan Goslin, Sheldon Modeland, Mr. Chris Kallos, Mr. Peter Thorne, Ms. Bridie Barratt Schmidt, Imran Akram, Mr. John Buckland, Mr. Arun George, Andrew Saunders, John Kidd, Mr. Will Forbes, Alastair George, Mr. Mark Cartlich, Franc Gregori, James Carthew, Dr. Michael Aitkenhead, Mr. Gavin Wood, Dr. Jason Zhang, Zsolt Mester, Luke Poloniecki, Pooya Hemami, Mr. Peter Chilton, Dr. Philippa Gardner, Iain Daly, Amit Dayal, Mark Hodges, Bruce McKay, Teea Reijonen, Rob Kirtley, Graeme Kyle, Victoria Buxton, Ian Kellett, Andrew Mitchell, Mr. Michael Stoner, Ian Berry, Ian Mitchell, Jonathan Helliwell, Toby Gordon, Wayne Atwell, William Atcheson, Xavier Grunauer MAY 2013 EDITION OF EDISON INSIGHT 152 $10 View Abstract
30-May-13 S&P Capital IQ Factual Report N/A EpiCept Corp 11 $126.50 View Abstract
30-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Epicept Corporation 40 $460 View Abstract
Next 1

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.